Inflammasome Therapeutics' K8 Slows Geographic Atrophy Lesion Growth by 54% and Shows Visual-Acuity Benefit in Phase 2 Trial

Inflammasome Therapeutics (搜索)搜索该词条 today announced positive six-month Phase 2 results for its investigational drug K8 (kamuvudine-8) (搜索)搜索该药品 in geographic atrophy (搜索)搜索该疾病 (GA), demonstrating a 54% reduction in mean lesion growth rate and a statistically significant visual-acuity advantage over control eyes. The findings, presented by Professor Jayakrishna Ambati, MD, of the University of Virginia at the American Society of Retina Specialists Annual Meeting in Montreal, position K8 as a potential next-generation therapy for a disease affecting an estimated eight million people worldwide, including approximately 1.5 million in the US and 2.5 million in Europe.

In the 0.7 mg cohort, the mean rate of GA growth was 54% lower than in the pooled control group over six months, using the FDA-preferred linear mixed-effects slope analysis (two-sided p=0.016). A prespecified analysis restricted to eyes with extrafoveal lesions — those with the greatest potential for vision preservation — showed a covariate-adjusted 4.0-ETDRS-letter mean advantage in best-corrected visual acuity (BCVA) for K8-treated eyes versus all control eyes over six months (two-sided p=0.004). BCVA changes were positive at every visit in the K8 group and negative at every visit in controls.

A dual mechanism targeting multiple toxic drivers

K8 is an investigational dual inflammasome (搜索)搜索该靶点 inhibitor delivered as a bioerodible, sustained-release intravitreal implant dosed once every three months. Unlike currently approved therapies that target single complement pathway components, K8 is designed to block inflammasome activation triggered by multiple toxic drivers of GA — including complement, retrotransposons, and oxidative stress — rather than a single upstream pathway. K8 remains fully investigational and has not been approved by the FDA or any other regulatory authority.

Professor Ambati, Director of the Center for Advanced Vision Science and DuPont Guerry, III Professor of Ophthalmology at the University of Virginia, and founder of Inflammasome Therapeutics (搜索)搜索该词条, said: "Clearing the high bar of 50% in slowing lesion growth and preserving or improving visual function suggests that K8 not only stops retinal cells from dying but also improves the function of distressed cells by reducing inflammation. The statistical significance of K8's lesion-growth reduction fulfills the promise of earlier studies, which predicted that a drug with strong efficacy could demonstrate a statistically significant effect in GA with 30 patients. The dual benefit of K8 on structure and function should now be confirmed in Phase 3 studies."

Trial design and safety profile

The multicenter Phase 2 trial enrolled 30 participants with bilateral GA across nine US centers — totaling 60 eyes — with the worse-seeing eye receiving a K8 implant and the fellow eye serving as an untreated control. Three doses (0.3 mg, 0.7 mg, and 1.05 mg) were tested, administered at baseline and again at month three. The fellow-eye control design strengthens the internal consistency of results, as natural-history data cited by the company indicate GA progresses at nearly identical rates between a patient's two eyes absent treatment.

No drug-related serious adverse events or dose-limiting toxicities were reported through month six. There were no cases of endophthalmitis, intraocular inflammation, neovascular AMD, retinal vasculitis, or optic neuropathy. The results extend an earlier readout from the same trial, which showed a 66% reduction in lesion growth at three months in an initial five-patient cohort — a result the company used to justify expanding enrollment to 60 eyes.

Context within the current treatment landscape

Two therapies are currently approved in the US for GA: Apellis Pharmaceuticals查看公司主页' Syfovre (pegcetacoplan) (搜索)搜索该药品, a complement C3 inhibitor cleared in February 2023, and Astellas查看公司主页' Izervay (avacincaptad pegol) (搜索)搜索该药品, a complement C5 inhibitor approved in August 2023. Over the first six months of dosing, both reduced the mean rate of GA growth by approximately 13–14% versus controls, and neither reported a visual-acuity benefit in its Phase 3 trials. All three K8 dose cohorts slowed mean GA growth against the pooled control group substantially more than those benchmarks, though cross-trial comparisons are not based on head-to-head studies.

Neither approved therapy has secured EMA approval, reportedly reflecting European regulators' emphasis on functional vision outcomes rather than anatomic lesion measures alone. The visual-acuity finding is what distinguishes this readout from prior GA trials. Both approved drugs demonstrated anatomic effects — slower lesion expansion — without translating into measurable functional benefit, a disconnect that has tempered enthusiasm among retina specialists about their real-world impact.

The dosing interval represents a further point of contrast. K8's implant is designed for administration every three months, versus monthly or near-monthly injections for the approved complement inhibitors — a difference that, if durability holds up in larger studies, could reduce the treatment burden that has limited real-world uptake of existing GA therapies.

Limitations and next steps

Caution is warranted given the sample size: the BCVA analysis was conducted in just 30 eyes (14 treated, 16 control), and the primary efficacy analysis, while statistically significant, comes from a single Phase 2 study rather than a confirmatory trial. Inflammasome Therapeutics (搜索)搜索该词条 has said it plans to move directly into a global Phase 3 pivotal program. If replicated in larger, randomized studies, a therapy that demonstrates both slower structural loss and preserved visual function would address one of the principal limitations of existing GA treatments.